Literature DB >> 33386288

Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.

Jeremie Calais1, Wesley R Armstrong2, Amar U Kishan3, Kiara M Booker2, Thomas A Hope4, Wolfgang P Fendler5, David Elashoff6, Nicholas G Nickols7, Johannes Czernin8.   

Abstract

The purpose of this randomized trial is to evaluate the success rate of salvage radiation therapy for recurrence of prostate cancer after radical prostatectomy, with and without planning based on prostate-specific membrane antigen positron emission tomography/computed tomography. Enrollment has been completed and patients are being followed for 5yr.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33386288      PMCID： PMC8057677          DOI： 10.1016/j.euf.2020.12.009

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  7 in total

1.  The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.

Authors:  Jeremie Calais; Minsong Cao; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2018-01-04       Impact factor: 10.057

2.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Authors:  Jeremie Calais; Johannes Czernin; Minsong Cao; Amar U Kishan; John V Hegde; Narek Shaverdian; Kiri Sandler; Fang-I Chu; Chris R King; Michael L Steinberg; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Thorsten Poeppel; Philipp Hetkamp; Francesco Ceci; Ken Herrmann; Wolfgang P Fendler; Matthias Eiber; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

3.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Authors:  Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

4.  Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

Authors:  Christian Carrie; Nicolas Magné; Patricia Burban-Provost; Paul Sargos; Igor Latorzeff; Jean-Léon Lagrange; Stéphane Supiot; Yazid Belkacemi; Didier Peiffert; Nedla Allouache; Bernard M Dubray; Stéphanie Servagi-Vernat; Jean-Philippe Suchaud; Gilles Crehange; Stéphane Guerif; Meryem Brihoum; Nicolas Barbier; Pierre Graff-Cailleaud; Alain Ruffion; Sophie Dussart; Céline Ferlay; Sylvie Chabaud
Journal:  Lancet Oncol       Date:  2019-10-16       Impact factor: 41.316

5.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Authors:  Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

6.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Authors:  Jeremie Calais; Johannes Czernin; Wolfgang P Fendler; David Elashoff; Nicholas G Nickols
Journal:  BMC Cancer       Date:  2019-01-07       Impact factor: 4.430

7.  Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.

Authors:  Claire L Vale; David Fisher; Andrew Kneebone; Christopher Parker; Maria Pearse; Pierre Richaud; Paul Sargos; Matthew R Sydes; Christopher Brawley; Meryem Brihoum; Chris Brown; Sylvie Chabaud; Adrian Cook; Silvia Forcat; Carol Fraser-Browne; Igor Latorzeff; Mahesh K B Parmar; Jayne F Tierney
Journal:  Lancet       Date:  2020-09-28       Impact factor: 79.321
  7 in total
  6 in total

1.  Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

Authors:  Hossein Jadvar; Jeremie Calais; Stefano Fanti; Felix Feng; Kirsten L Greene; James L Gulley; Michael Hofman; Bridget F Koontz; Daniel W Lin; Michael J Morris; Steve P Rowe; Trevor J Royce; Simpa Salami; Bital Savir-Baruch; Sandy Srinivas; Thomas A Hope
Journal:  J Nucl Med       Date:  2021-09-30       Impact factor: 11.082

2.  Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.

Authors:  Francesco Ceci; Guido Rovera; Giuseppe Carlo Iorio; Alessia Guarneri; Valeria Chiofalo; Roberto Passera; Marco Oderda; Sara Dall'Armellina; Virginia Liberini; Serena Grimaldi; Marilena Bellò; Paolo Gontero; Umberto Ricardi; Désirée Deandreis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-26       Impact factor: 10.057

3.  PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.

Authors:  Justin Ferdinandus; Wolfgang P Fendler; Andrea Farolfi; Samuel Washington; Osama Mohamad; Miguel H Pampaloni; Peter J H Scott; Melissa Rodnick; Benjamin L Viglianti; Matthias Eiber; Ken Herrmann; Johannes Czernin; Wesley R Armstrong; Jeremie Calais; Thomas A Hope; Morand Piert
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

4.  Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer.

Authors:  Francesco Ceci; Gennaro Musi; Ottavio De Cobelli
Journal:  Eur Urol Open Sci       Date:  2021-10-30

Review 5.  PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.

Authors:  Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

6.  Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.

Authors:  Vasileios Karagiannis; Viktor Wichmann; Juha Saarinen; Natalja Eigeliene; Heidi Andersen; Antti Jekunen
Journal:  Radiat Oncol       Date:  2022-01-29       Impact factor: 3.481
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.